Trimetazidine, an Anti-Ischemic Drug, Reduces the Antielectroshock Effects of Certain First-Generation Antiepileptic Drugs

Trimetazidine (TMZ), an anti-ischemic drug for improving cellular metabolism, is mostly administered to patients with poorly controlled ischemic heart disease (IHD). Since IHD is considered the most frequent causative factor of cardiac arrhythmias, and these often coexist with seizure disorders, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Borowicz-Reutt, Kinga, Banach, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570019/
https://www.ncbi.nlm.nih.gov/pubmed/36232629
http://dx.doi.org/10.3390/ijms231911328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570019/
https://www.ncbi.nlm.nih.gov/pubmed/36232629
http://dx.doi.org/10.3390/ijms231911328

Ejemplares similares